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Summary
 
Using fluorescent HLA-A
 
*
 
0201 tetramers containing the immunodominant Melan-A/MART-1
(Melan-A) tumor-associated antigen (Ag), we previously observed that metastatic lymph nodes
of melanoma patients contain high numbers of Ag-experienced Melan-A–specific cytolytic T
lymphocytes (CTLs). In this paper, we enumerated and characterized ex vivo Melan-A–spe-
cific cells in peripheral blood samples from both melanoma patients and healthy individuals.
High frequencies (
 
$
 
1 in 2,500 CD8
 
1
 
 T cells) of Melan-A–specific cells were found in 10 out
of 13 patients, and, surprisingly, in 6 out of 10 healthy individuals. Virtually all Melan-A–spe-
cific cells from 6 out of 6 healthy individuals and from 7 out of 10 patients displayed a naive
CD45RA
 
hi
 
/RO
 
2
 
 phenotype, whereas variable proportions of Ag-experienced CD45RA
 
lo
 
/
RO
 
1
 
 Melan-A–specific cells were observed in the remaining 3 patients. In contrast, ex vivo
influenza matrix–specific CTLs from all individuals exhibited a CD45RA
 
lo
 
/RO
 
1
 
 memory
phenotype as expected. Ag specificity of tetramer-sorted A2/Melan-A
 
1
 
 cells from healthy indi-
viduals was confirmed after mitogen-driven expansion. Likewise, functional limiting dilution
analysis and interferon 
 
g
 
 ELISPOT assays independently confirmed that most of the Melan-A–
specific cells were not Ag experienced. Thus, it appears that high frequencies of naive Melan-
A–specific CD8
 
1
 
 T cells can be found in a large proportion of HLA-A
 
*
 
0201
 
1
 
 individuals. Fur-
thermore, as demonstrated for one patient followed over time, dramatic phenotype changes of
circulating Melan-A–specific cells can occur in vivo.
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A
 
ccumulating evidence supports the importance of Ag-
specific cytolytic T lymphocyte (CTL) responses in
tumor immunity. Moreover, the molecular identification
of CTL-defined tumor-associated Ags has prompted the
design of novel Ag-specific cancer vaccines (1–3). Indeed,
numerous phase I clinical trials are underway aimed at in-
ducing CTL responses against defined tumor Ags. In par-
ticular, the Melan-A/MART-1 (Melan-A)
 
1
 
 gene, which is
expressed by normal melanocytes and by most fresh mela-
noma samples, codes for Ags recognized by tumor-reactive
HLA-A
 
*
 
0201–restricted CTLs (4, 5). CTL lines specific for
the immunodominant Melan-A
 
26–35
 
 Ag derived from pe-
ripheral blood of both melanoma patients and healthy indi-
viduals were obtained after repeated antigenic stimulation
in vitro (6–8). There has been suggestive evidence that
Melan-A–specific cells may present distinct naive and
memory phenotypes in healthy individuals and melanoma
patients, respectively (8, 9). However, the lack of direct as-
says had prevented a precise assessment of CTLs ex vivo
(10, 11). The development of HLA-A
 
*
 
0201 tetrameric
complexes containing melanoma-derived antigenic pep-
tides has enabled direct enumeration and phenotyping of
tumor-specific CTLs. For instance, we recently reported
 
1
 
Abbreviations used in this paper:
 
 CTL, cytolytic T lymphocyte; CTLp, cy-
tolytic T lymphocytes precursor(s); LDA, limiting dilution analysis; Melan-A,
Melan-A/MART-1.
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the presence of high numbers of Ag-experienced tumor-
specific CTLs in metastatic LNs of melanoma patients (12).
In this study, the characterization of HLA-A
 
*
 
0201–
restricted Melan-A–specific CD8
 
1
 
 T cells has been ex-
tended to the peripheral blood compartment from both
melanoma patients and healthy individuals. Cells were ana-
lyzed for surface expression of naive-, effector-, and mem-
ory-type–associated markers. In humans, the CD45RA and
CD45RO surface Ags have been used to identify naive and
memory T cells, respectively (13–15). However, these two
Ags may be insufficient, as the CD45RA
 
hi
 
 population con-
tains cells that express several phenotypic features of primed
T cells (16–18). Indeed, CD45RA
 
hi
 
 cells lacking surface
expression of the CD28 costimulatory receptor exhibit di-
rect ex vivo cytolytic activity (19, 20), and abundantly ex-
press Fas ligand transcripts as well as perforin and granzyme
B (21, 22), thereby displaying the attributes of effector
CTLs (22, 23). Accordingly, a model has been proposed in
which naive-, effector-, and memory-type CD8
 
1
 
 T cells
could be distinguished based on surface expression of
CD28 and CD45RA (24). We have applied this model on
the level of single Ag-specific cells in multiparameter analy-
ses including CD28, CD45RA, and CD45RO surface ex-
pression and fluorescent tetramers containing the Melan-
A
 
26–35
 
 A27L peptide (A2/Melan-A) or the influenza matrix
Flu-MA
 
58-66
 
 (A2/Flu-MA) Ag. Since the majority of HLA-
A
 
*
 
0201 individuals are sensitized against the latter immu-
nodominant peptide (25), it served as a source of well-
defined memory-type, epitope-specific CTL populations in
circulating lymphocytes (26).
Ex vivo tetramer staining generally revealed high fre-
quencies of A2/Melan-A
 
1
 
CD8
 
1
 
 T cells. Surprisingly, in
the majority of individuals these cells displayed a naive
CD28
 
1
 
CD45RA
 
hi
 
/RO
 
2
 
 phenotype, in contrast to the
CD28
 
1
 
CD45RA
 
lo
 
/RO
 
1
 
 memory phenotype exhibited by
most A2/Flu-MA
 
1
 
 cells. Both specificity and phenotype of
A2/Melan-A
 
1
 
 cells were independently confirmed by
functional assays.
 
Materials and Methods
 
Cells.
 
13 patients (22–75 yr old) with advanced stage malig-
nant melanoma and 10 healthy donors (22–73 yr old) were se-
lected for this study on the basis of HLA-A2 Ag expression as as-
sessed by flow cytometry of PBMCs stained with allele-specific
mAb BB7.2 (27). Molecular HLA-A
 
*
 
02 subtyping performed by
PCR–sequence-specific oligonucleotide probe (SSOP) (28) re-
vealed that all HLA-A2
 
1
 
 individuals were A
 
*
 
0201. None of them
had two different A
 
*
 
02 subtypes. PBMCs from healthy blood do-
nors were obtained from buffy coats provided by the blood trans-
fusion center in Lausanne, Switzerland. PBMCs were separated
from heparinized blood diluted 1:2 with PBS by centrifugation
over Ficoll-Paque (Pharmacia), washed three times, and cryopre-
served in RPMI 1640/40% FCS/10% DMSO. Vials containing
10
 
7
 
 PBMCs were stored in liquid nitrogen.
 
Tetramers.
 
Tetrameric complexes were synthesized as previ-
ously described (12, 26). In brief, purified HLA heavy chain and
 
b
 
2-microglobulin were synthesized using a prokaryotic expres-
sion system (pET; R&D Systems, Inc.). The heavy chain was
modified by deletion of the transmembrane cytosolic tail and
COOH addition of a sequence containing the BirA enzymatic
biotinylation site. Heavy chain, 
 
b
 
2-microglobulin, and peptide
were refolded by dilution. The 45-kD refolded product was iso-
lated by fast protein liquid chromatography, then biotinylated by
BirA (Avidity) in the presence of biotin, adenosine 5
 
9
 
-triphos-
phate, and Mg
 
2
 
1
 
 (all from Sigma Chemical Co.). Streptavidin-PE
conjugate (Sigma Chemical Co.) was added in a 1:4 molar ratio,
and the tetrameric product was concentrated to 1 mg/ml. Tet-
ramers were synthesized around two tumor antigenic peptides
recognized by HLA-A
 
*
 
0201–restricted CTLs, both of which de-
rive from melanocyte lineage-specific proteins. One peptide was
the natural tyrosinase
 
368–376
 
 epitope (the N370D variant, YMD-
GTMSQV, generated by Ag processing [29]); the other was a
modification of the Melan-A
 
26–35
 
 epitope (30). This modified
epitope, ELAGIGILTV, carrying a substitution of Ala for Leu at
position 2 from the NH
 
2
 
 terminus (hereafter A27L), forms rela-
tively stable complexes with HLA-A
 
*
 
0201 and is a more potent
immunogen than is the natural Melan-A peptide (31, 32). Exper-
iments have shown that tetramers synthesized around the A27L-
modified epitope generally stained polyclonal and monoclonal
Melan-A–specific CTL populations (data not shown and refer-
ence 12). However, we can not totally exclude the possibility
that some T cell populations might not have been stained with
the A27L peptide analogue containing tetramer. Finally, a third
tetramer was synthesized around the HLA-A
 
*
 
0201–restricted in-
fluenza matrix Flu-MA
 
58-66
 
 (GILGFVFTL) immunodominant
peptide. A2/tyrosinase, A2/Melan-A, and A2/Flu-MA tetramers
were used at 20 
 
m
 
g/ml.
 
mAbs.
 
Anti-CD3
 
PE
 
, CD8
 
FITC, PerCP
 
, and CD45RA
 
Cyc
 
 were
obtained from Becton Dickinson; anti-CD45RO
 
FITC
 
 was from
DAKO Corp.; and anti-CD28
 
FITC
 
 was from Immunotech.
 
Flow Cytometry Analysis.
 
Thawed PBMCs were cultured for
16–20 h in IMDM supplemented with 0.55 mM Arg, 0.24 mM
Asn, 1.5 mM Gln, and 8% pooled human A
 
1
 
 serum (complete
medium). CD8
 
1
 
 lymphocytes were then purified from PBMCs
in two rounds of positive selection by magnetic cell sorting using
a MiniMACS device (Miltenyi Biotec Inc.) The resulting cells
were 
 
.
 
98% CD3
 
1
 
CD8
 
1
 
, and 10
 
6
 
 were stained with A2/tetramers
and FITC and Cychrome mAb conjugates in 50 
 
m
 
l of PBS, 2%
BSA, and 0.2% azide for 40 min at 4
 
8
 
C. CD8 enrichment did not
disturb the detection of tetramer
 
1
 
 cells, either in terms of fre-
quency or phenotype (data not shown). Cells were then washed
once in the same buffer and analyzed immediately in a FACSCal-
ibur
 
®
 
 (Becton Dickinson).
 
Limiting Dilution Analysis.
 
CD45RA
 
lo
 
 and CD45RA
 
hi
 
CD8
 
1
 
T cells subsets from healthy donors HD 329 and HD 604 and
from melanoma patients LAU 132 and LAU 203 were sorted us-
ing a FACStar
 
®
 
 (Becton Dickinson). These subpopulations were
cultured at 10,000, 5,000, 2,500, and 1,250 cells/well (24 wells
per condition) in complete medium plus 100 U/ml recombinant
human IL-2, and stimulated at days 0 and 7 by autologous CD8
 
2
 
PBMCs (10
 
5
 
/well) pulsed with 1 
 
m
 
M Melan-A
 
26–35
 
 A27L pep-
tide. At day 13, Ag recognition was assessed using T2 target cells
(100 
 
m
 
l) labeled with 
 
51
 
Cr and incubated in the presence or ab-
sence of 1 
 
m
 
g/ml of the antigenic Melan-A
 
26–35
 
 A27L peptide for
1 h at 37
 
8
 
C and washed three times. Labeled target cells (10
 
3
 
 cells
in 50 
 
m
 
l) were then added to effector cells (50 
 
m
 
l) in V-bottomed
microwells (50 
 
m
 
l). The effector cells were preincubated for 20
min at 37
 
8
 
C in the presence of unlabeled K562 cells (5 
 
3
 
 10
 
5
 
/
well) to eliminate nonspecific lysis due to NK-like effectors. Cr
release was measured in supernatant (40 
 
m
 
l) harvested after 4 h of
incubation at 37
 
8
 
C. The percentage of specific lysis and the de-
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duced frequency of CTL precursors (CTLp) present in each sub-
set was calculated as previously described (33).
 
IFN-
 
g
 
 ELISPOT Assay.
 
ELISPOT plates (Millipore) were
coated overnight with antibody to human IFN-
 
g
 
 (Mabtech) and
washed six times. 10 
 
m
 
g/ml peptide and 1.66 
 
3
 
 10
 
5
 
 PBMCs per
well in 200 ml Iscove’s medium/8% human serum were added
and incubated for 20 h at 378C. Assays were performed in six
replicates with either the Melan-A26–35 A27L or the Flu-MA58–66
peptide. The ILKEPVHGV Pol476–484 peptide from the reverse
transcriptase of HIV-1 was also included as a negative control.
(All subjects in this study were HIV seronegative.) Cells were re-
moved, and plates were developed with a second antibody to hu-
man IFN-g (biotinylated) and streptavidin-alkaline phosphatase
(Mabtech). The deduced frequency of peptide-specific CTLs in
CD81 T cells was calculated as: (mean no. of specific spots) / [(1.66 3
105) 3 (percentage of CD31CD81 cells in PBMCs)], where the
percent of CD31CD81 cells in PBMCs was determined by flow
cytometry on the same batch of cryopreserved cells. The baseline
number, or cut off value, of nonspecific IFN-g spots was calcu-
lated as the mean number of spots in the presence of the control
HIV-1 peptide in 21 individuals 1 3 SD. This value was 17
spots/106 PBMCs (mean 5 5 spots/106 PBMCs, SD 5 4), im-
plying a lower specific detection limit of 1 in z60,000 PBMCs.
Since the enumeration of Melan-A–specific lymphocytes with
tetramers was directly performed on gated CD81 lymphocytes,
the cut off value and the frequencies determined by IFN-g
ELISPOT were all adjusted to reflect the percentage of CD81
lymphocytes determined in the same PBMC batch by flow cy-
tometry. This was performed to enable comparison with tetramer
frequency values. The CD8-adjusted baseline spot value was 87
spots/106 CD81 PBMCs (mean 5 25 spots/106 CD81 PBMCs,
SD 5 21).
Results
Circulating A2/Melan-A1CD81 T Cells Are Detectable both
in Melanoma Patients and Healthy Individuals. 13 HLA-A21
patients with advanced stage malignant melanoma and 10
HLA-A21 healthy donors were randomly selected for this
study. Among melanoma patients, three presented concur-
rent vitiligo that developed either after a systemic treatment
with intravenous IL-2 1 Cis Platinum 1 IFN-a (patient
LAU 155), during IFN-a therapy (LAU 156), or after iso-
lated limb perfusion with high dose of TNF-a 1 mel-
phalan (LAU 269).
Highly enriched circulating CD81 T lymphocytes
(.98% CD31CD81) from each individual were stained for
flow cytometry with different A2/tetramers, two synthe-
sized around melanoma-associated Ags, namely the Melan-
A26–35 A27L analogue and tyrosinase368–376, and one around
the viral influenza matrix Flu-MA58–66 peptide. As illus-
trated in Fig. 1, circulating A2/Melan-A1 and A2/Flu-
MA1CD81 cells were detected both in melanoma patients
and healthy donors. In contrast, the frequency of A2/
tyrosinase1 cells was generally too low for direct ex vivo
detection. However, we observed that a short in vitro Ag-
driven expansion was sufficient to detect A2/tyrosinase1
cells in the majority of A2/melanoma patients, confirming
the presence of circulating tyrosinase specific CTLp (33a).
To determine the levels of nonspecific A2/tetramer
staining of circulating CD81 T cells, a series of nine blood
samples of randomly selected HLA-A22 blood donors was
analyzed (Table I). Although this approach does not pro-
vide direct insight on the level of nonspecific epitope-based
A2/tetramer staining in HLA-A21 individuals, it allowed
us to define a lower detection limit for tetramer staining in
A21 individuals. This lower detection limit was z0.04% of
CD81 T cells with A2/Melan-A tetramers (cut off 5 mean 1
3 SD 5 0.036), and ,0.02% of CD81 T cells with A2/
Flu-MA tetramers (cut off 5 mean 1 3 SD 5 0.011).
These detection limits for staining with A2/Melan-A tet-
ramers are clearly lower for circulating cells than for tumor-
infiltrated LNs (z0.25%; calculated previously; reference
12). According to these limits, ex vivo circulating A2/
Melan-A1CD81 cells were found in significant numbers in
10 out of 13 melanoma patients, and in 6 out of 10 healthy
donors. As we previously reported (34), the frequency of
A2/Melan-A1 cells was generally very high in melanoma
patients with concurrent vitiligo (mean 5 0.23% of CD81
cells). In contrast, the frequency of CD81 cells stained with
A2/Melan-A tetramers was comparable between mela-
noma patients without vitiligo and healthy donors (mean 5
Figure 1. Detection of ex vivo circulating A2/Melan-A1 and A2/Flu-
MA1, but not A2/Tyrosinase1CD81 T cells by flow cytometry, in a
melanoma patient (LAU 233) and a healthy donor (HD 329). Highly ho-
mogeneous CD81 lymphocyte populations (.98%) were obtained from
PBMCs of patient LAU 233 or from healthy donor HD 329, by two
rounds of positive selection with magnetic cell sorting. The lymphocyte
preparations were then stained with A2/Melan-A, A2/Tyrosinase, or
A2/Flu-MA tetramers together with anti-CD8FITC mAb, and analyzed
immediately by flow cytometry. The frequency of up to 0.01% of
A2/tyrosinase1 cells was below the limit of detection ($0.04% for A2/
Melan-A; $0.02% for A2/Flu-MA).
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0.07%) (Table I). Likewise, the frequency of A2/Flu-MA1
cells was globally equivalent in all groups, with the excep-
tion of LAU 198, who had 1.65% of CD81 cells stained
with tetramers.
Circulating A2/Melan-A1 and A2/Flu-MA1CD81 T Cells
in Healthy Individuals Present Naive and Memory Phenotypes,
Respectively. In humans, cell surface expression of the
CD45RA and CD45RO isoforms have been used to iden-
tify naive and memory T cells, respectively (13–15). As cir-
culating CD282CD81 T cells present direct ex vivo cy-
tolytic activity (19, 20) and were recently proposed to
correspond to effector-type CTLs (22–24), individuals pre-
senting significant amounts of circulating A2/Melan-A1
and A2/Flu-MA1 cells were phenotyped for CD28, CD45RA,
and CD45RO surface expression by three-color flow cy-
tometry analyses.
Clearly, circulating A2/Melan-A1 and A2/Flu-MA1
CD81 T cells from healthy donors displayed distinct phe-
notypes (as illustrated for one donor in Fig. 2 A and sum-
marized in Fig. 2 C). Practically all of the A2/Melan-A1
cells were CD281CD45RAhi/RO2 (range: 84–95%), cor-
responding to a naive phenotype. In marked contrast, most
of A2/Flu-MA1 cells were CD45RAlo/RO1 (range: 83–
97%). Thus, the phenotype of A2/Flu-MA1 cells corre-
sponded to Ag-experienced memory T cells, compatible
with the notion that the Flu-MA58–66 peptide probably rep-
resents a recall Ag in these HLA-A21 individuals. In addi-
tion, z20% of CD45RAlo/RO1A2/Flu-MA1 cells from
HD 099 and HD 604 presented a CD282 phenotype (data
not shown).
Circulating A2/Melan-A1CD81 T Cells of Some Melanoma
Patients Consist of Variable Proportions of Naive and Ag-experi-
enced Phenotypes. In contrast to healthy individuals, the
phenotype of A2/Melan-A1 cells was heterogeneous in
melanoma patients (Fig. 2 B). In most of them (7 out of
10), A2/Melan-A1 cells presented a uniformly naive
CD281CD45RAhi/RO2 phenotype (range: 81–95%), like
those found in all healthy donors. However, 3 out of 10
patients either displayed .35% CD45RAlo/RO1 (LAU
132 and 240), or .90% CD282CD45RAint (LAU 156)
A2/Melan-A1 cells (Fig. 2 C). It is not possible with the
current data to determine whether such phenotypic changes
in Melan-A–specific lymphocytes may have occurred in re-
sponse to peptide-based vaccination (LAU 132 received
five rounds of vaccination with the Melan-A26–35 peptide
plus other melanoma-associated Ags with GM-CSF), or
simply reflect non-Ag-specific changes after administration
of cytokines such as GM-CSF or IFN-a (LAU 132 re-
ceived GM-CSF concomitant with peptide administration,
and LAU 156 was treated with IFN-a). Moreover, other
melanoma patients included in this study who also received
Melan-A26–35 peptide vaccination with GM-CSF (LAU
269) or IFN-a therapy (LAU 267) did not present memory
phenotype A2/Melan-A1 cells in the circulating compart-
ment.
Altogether, phenotype and frequency of A2/Melan-A1
cells were generally not correlated, since (a) memory phe-
notype cells detected in patients LAU 132 and 240 were
not found at increased frequencies (0.07 and 0.04% of
CD81 T cells, respectively); and (b) high frequencies of
Table I. Percentage of Circulating A2/Melan-A1 and A2/Flu-MA1 Subsets in CD81 T Cells*
HLA-A2–negative
healthy donors
HLA-A*0201
healthy donors
HLA-A*0201
melanoma patients
HLA-A*0201 melanoma
patients 1 vitiligo
Name Melan-A Flu-MA Name Melan-A Flu-MA Name Melan-A Flu-MA Name Melan-A Flu-MA
HD 001 0.01 0.01 HD 006 0.05 0.11 LAU 50 0.03‡ 0.41 LAU 155 0.12 0.07
HD 004 0.00 0.00 HD 007 0.01‡ 0.07 LAU 56 0.08 0.13 LAU 156 0.40 0.18
HD 048 0.01 0.00 HD 008 0.06 0.02 LAU 97 0.07 0.10 LAU 269 0.16 0.02
HD 108 0.01 0.00 HD 099 0.08 0.07 LAU 132§ 0.07 0.05
HD 143 0.03 0.00 HD 301 0.02‡ 0.09 LAU 198 0.02‡ 1.65
HD 222 0.02 0.00 HD 304 0.03‡ 0.05 LAU 203 0.07 0.03
HD 299 0.01 0.00 HD 329 0.10 0.17 LAU 212 0.03‡ 0.05
HD 347 0.01 0.00 HD 421 0.11 0.03 LAU 233 0.21 0.08
HD 408 0.01 0.00 HD 422 0.02‡ 0.49 LAU 240 0.04 ND
HD 604 0.21 0.13 LAU 267 0.04 ND
Mean 0.014 0.001 Mean 0.07 0.12 Mean 0.07 0.31 Mean 0.23 0.09
SD 0.008 0.003 SD 0.06 0.14 SD 0.06 0.55 SD 0.15 0.08
C.O. 0.036 0.011
*The percentages of tetramer1 cells were determined as illustrated in Fig. 1. Values are the mean of duplicates.
‡Percentage values below the lower limit of detection, as determined with the nine HLA-A2–negative healthy donors (cut off [C.O.] 5 mean 1 3 SD).
§Analysis of LAU 132 was performed with sample from September 1997.
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A2/Melan-A1 cells (.0.2% CD81 T cells) in patients LAU
155, 233, and 269 as well as in healthy donor HD 604 were
not of the memory phenotype. As an exception, LAU 156
presented high frequency of CD282A2/Melan-A1 cells.
The vast majority of A2/Flu-MA1 cells displayed a
memory-like CD281CD45RAlo/RO1 phenotype in 11
out of 13 patients, as well as in all healthy donors (Fig. 2
C). However, the A2/Flu-MA1 cells presented both
CD282CD45RAint (60%) and CD281CD45RAint (30%)
phenotypes in LAU 156, and a CD281CD45RAint pheno-
type in LAU 269 (CD28 phenotype not shown).
Confirmation of Ag-specificity and Functional Status of A2/
Melan-A1 Cells by Limiting Dilution Analysis and IFN-g
ELISPOT Assays. Initially, two healthy donors (HD 329
and 604) and two melanoma patients (LAU 132 and 203)
were selected according to the phenotype of A2/Melan-A1
cells: the vast majority of A2/Melan-A1 cells from HD 329,
HD 604, and LAU 203 were CD45RAhi (95, 95, and 94%,
respectively); on the other hand, 46% of those from LAU 132
presented a CD45RAlo phenotype (Table II). These pheno-
types were independently examined by two functional assays,
limiting dilution analysis (LDA) and IFN-g ELISPOT.
Figure 2. Phenotypic analysis
of ex vivo circulating A2/
Melan-A1 and A2/Flu-MA1
cells in melanoma patients and
healthy donors. CD81 lympho-
cyte populations were highly pu-
rified (.98%) from PBMCs, as
illustrated in Fig. 1. The lym-
phocyte preparations were then
stained with A2/Melan-A, or
A2/Flu-MA tetramers together
with anti-CD45RACYC and ei-
ther anti-CD45ROFITC or anti-
CD28FITC mAbs, and immediately
analyzed by flow cytometry. (A)
Pattern of expression of
CD45RA/RO (top) or
CD45RA/CD28 (bottom) in
total circulating CD81 T cells
(left) from healthy donors
(shown is HD 329). They were
CD281CD45RAhi/RO2 in A2/
Melan-A1 gated cells (middle)
but CD281CD45RAlo/RO1 in
A2/Flu-MA1 gated cells (right).
(B) Circulating A2/Melan-
A1CD81 T cells detected in the
majority (7 out of 10) of mela-
noma patients presented a
CD281CD45RAhi/RO2 phenotype (left). In contrast, tetramer1 cells from 2 out of 10 patients displayed variable proportions of CD45RAhi/RO2 and
CD45RAlo/RO1tetramer1 cells (middle) and a CD282CD45RAint phenotype for 1 out of 10 patients (right). (C) Summary of phenotyping data ob-
tained for melanoma patients and healthy donors. Frequencies of CD45RAlo cells detected in gated A2/Melan-A1 and A2/Flu-MA1CD81 T cells were
calculated with CellQuest™ software.
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For LDA, CD45RAlo and CD45RAhi fractions of
CD81 T cells were sorted and stimulated twice with
Melan-A26–35 A27L peptide at limiting dilution conditions.
After 13 d, the large majority of microcultures displaying
Melan-A–specific CTL activity in HD 329, HD 604, and
LAU 203 were detected in the progeny from the
CD45RAhi subset (98, 99, and 90% of positive microcul-
tures, respectively). In contrast, 73% of positive microcul-
tures in LAU 132 were detected in the cells expanded from
the CD45RAlo subset. Thus, the distribution of CTLp
among the naive and memory subsets evaluated by func-
tional LDA assays parallels that observed by flow cytometry
phenotypic analysis, confirming the Ag specificity of the
relatively low numbers of tetramer1 lymphocytes. How-
ever, LDA underestimated the frequency of Melan-A–spe-
cific CTLp by a factor of z3 for CD45RAlo phenotype
A2/Melan-A1 cells (LAU 132), and to a higher extent by a
factor of z13 in average for CD45RAhi phenotype A2/
Melan-A1 cells (Table II).
In parallel, the phenotype of Melan-A–specific cells was
indirectly assessed by a 20-h IFN-g ELISPOT assay. Given
the limited number of cells available, this assay was not per-
formed on CD45RA1/2 sorted populations, but rather
with unsorted PBMCs. As expected for truly naive CD81
T cells, ex vivo Melan-A–specific IFN-g producing cells
were undetectable in PBMCs from HD 329, HD 604, and
LAU 203 (Table II). In contrast, for LAU 132, we found
z100 IFN-g–specific spots/106 CD81 T cells, which rep-
resented a significant frequency above background levels
(calculated as described below). To further investigate ex
vivo IFN-g production in response to challenge with Ag,
both Melan-A– and Flu-MA–specific cells from all healthy
donors and melanoma patients (except LAU 240 and 267)
were analyzed (Fig. 3). First, we determined a lower detec-
tion limit (cut off) for this assay. This cut off, based on the
number of nonspecific spots obtained after stimulation with
the irrelevant HIV-1 Pol468–476 peptide of PBMCs from the
21 individuals analyzed, was z90 spots/106 CD81 T cells
(cut off 5 mean 1 3 SD 5 87, see Materials and Methods
for details). With this detection limit, the frequencies of
Flu-MA–specific IFN-g–producing cells (Fig. 3 A) reached
significant levels for 17 out of 21 individuals. Moreover,
these frequencies correlated well with those calculated by
tetramers (P , 0.0001, linear regression analysis), but were
systematically underestimated (median, 3 times; min, 1.5
times; max, 15 times). In marked contrast, ex vivo Melan-
A–specific cells generally did not produce IFN-g, as ex-
pected for naive CD81 T cells (Fig. 3 B). Therefore, the
apparent frequency of Melan-A–specific IFN-g–producing
cells was generally much lower than that obtained by tet-
ramer staining (median, 30 times; min, 4 times; max,
infinite). It is worth noting that, as some patients had a
considerable fraction of A2/Melan-A1 cells with an Ag-
experienced phenotype (patients LAU 132 and LAU 156,
filled symbols in Fig. 3 B), the frequencies of IFN-g–pro-
ducing cells upon stimulation with the Melan-A peptide
analogue were less underestimated (seven and four times,
respectively), when compared with direct counting with
A2/Melan-A tetramers.
Naive A2/Melan-A1 Cells Are Ag-specific in Lytic Assays.
To rule out the possibility that the relatively low numbers
of Melan-A1 lymphocytes detected in A21 individuals was
the result of some flow cytometry artifacts, circulating A2/
Melan-A1/2 CD81 T cells from a healthy donor (HD 604)
were directly sorted into tetramer1 and tetramer2 popula-
tions. After 15 d of mitogen-driven polyclonal expansion (1
Table II. Frequency of Melan-A–specific Cells within CD81 T Cells Measured by Tetramer Staining, LDA, and IFN-g ELISPOT
Tetramers* LDA‡ ELISPOT§
CD45RAhi CD45RAlo CD45RAhi CD45RAlo total
HD 329i 100 7¶ 10 0.3 1¶
HD 604 200 10¶ 10 0.1 0.0¶
LAU 132 40 30 3 9 10
LAU 203 70 4¶ 10 1 0.0¶
All frequencies 31025.
*Values correspond to the number of cells in the A2/Melan-A1CD45RAhi and A2/Melan-A1CD45RAlo gates divided by the number of CD81
lymphocytes.
‡Sorted CD45RAhi and CD45RAlo fractions of CD81 T cells were stimulated twice with Melan-A26–35 A27L peptide at limiting dilution conditions,
then CTL activity was measured as described in Materials and Methods. The frequency of CTLp in each fraction was calculated using LDA analysis
software (33), then normalized to the percentages of the respective CD45RAhi and CD45RAlo subsets. Thus, the values indicated correspond to the
frequency, within CD81 T cells, of CD45RAhi and CD45RAlo Melan-A–specific CTLp, respectively.
§ Melan-A–specific IFN-g production and the deduced frequency of Melan-A–specific CTLs in CD81 T cells was measured as described in Materi-
als and Methods.
iTwo healthy donors (HD 329 and 604) and two melanoma patients (LAU 132 and 203) were selected. Analysis of LAU 132 was performed with
samples from September 1997. Values are the mean of duplicates, except for tetramer analysis of LAU 132 and 203, and are rounded to one signifi-
cant figure.
¶Frequencies below the lower limit of detection.
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mg/ml PHA-L, 100 U/ml IL-2, 10 ng/ml IL-7, and 5 3
105/ml autologous CD82 irradiated PBMCs), the tetramer1
fraction exhibited 10% A2/Melan-A1 cells, while the
tetramer2 fraction contained ,0.02% A2/Melan-A1 cells.
As expected, both populations displayed a homogeneous
CD45RAlo Ag-experienced phenotype (data not shown).
Each cell fraction was subsequently tested for its lytic activ-
ity. The polyclonal A2/Melan-A1 population specifically
killed T2 target cells pulsed with the natural or the A27L
analogue Melan-A26–35 peptides, whereas the A2/Melan-
A2 population did not (Fig. 4). This indicates the Ag spec-
ificity of cells stained with A2/Melan-A tetramers. More-
over, 9% of the whole A2/Melan-A1 population specifically
released IFN-g in ELISPOT assays, whereas the number of
IFN-g spots was insignificant for the A2/Melan-A2 popu-
lation (data not shown). This confirms that release of IFN-g
may be restricted to Ag-experienced phenotype specific
cells.
The Phenotype of A2/Melan-A1 Cells Can Dramatically
Fluctuate over Time. To assess the fate of Melan-A–specific
T cells in vivo, we followed Ag-specific lymphocytes by
tetramer staining in a series of blood samples from patient
LAU 132 taken over a period of 2 yr (Fig. 5). In this pa-
tient, a primary skin melanoma of the lower limb was diag-
nosed in October 1994. Inguinal LN dissection revealed
that 4 out of 6 nodes were infiltrated by melanoma cells.
The patient was treated with isolated limb perfusion with
melphalan, and subsequently received adjuvant IFN-a
therapy until April 1996, at which time he underwent a
second inguinal LN dissection (15 out of 16 positive LNs).
Figure 3. IFN-g ELISPOT
assay confirms the naive status of
most Melan-A–specific cells.
Frequency of Flu-MA– (A) and
Melan-A–specific (B) CTLs in
CD81 cells from 10 healthy do-
nors and 11 melanoma patients
(LAU 240 and 267 excepted)
was measured by both IFN-g
ELISPOT assay (x-axis) and tet-
ramer staining (y-axis), as de-
scribed in Materials and Meth-
ods. The phenotypes of
tetramer1 cells are as follows:
CD281CD45RAhi (s), CD281
CD45RAlo (j), 30–50% CD281
CD45RAlo (m) and .60% CD282
(r). The bars indicate the lower
detection limits for both tech-
niques. These were 0.4 3 1023
for A2/Melan-A, 0.1 3 1023 for
A2/Flu-MA (see footnote to Ta-
ble I for details), and 0.09 3
1023 for IFN-g ELISPOT (see
Materials and Methods for details).
Figure 4. Functional activity of PBMCs sorted according to their tet-
ramer staining phenotype correlates with Ag specificity. Ex vivo CD81
PBMCs from a healthy donor (HD 604) were sorted into A2/Melan-A
tetramer1 and tetramer2 populations. After 2 wk in the presence of irra-
diated autologous PBMCs and PHA, each cell fraction and a specific CTL
line was tested for its lytic activity against Cr-labeled T2 target cells pulsed
with different peptides: T2 cells alone (s), T2 1 Melan-A 26-35 (d);
and T2 1 Melan-A 26-35 A27L (j).
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The patient was tumor free from May 1996, then devel-
oped a brain metastasis diagnosed in December 1998. Im-
munization with melanoma-specific peptides was begun in
June 1996; he received a first immunization cycle consist-
ing of three or four weekly subcutaneous injections of 100
mg of each of the peptides Melan-A26–35, Tyrosinase1–9,
Tyrosinase368–376, gp100280–288, gp100457–466, and influenza
matrix Flu-MA58–66 in PBS. Four additional immunization
cycles were given in August and October 1996, then in
March and June 1997. All cycles with the exception of the
first included treatment with GM-CSF (daily subcutaneous
injections of 75 mg, starting 4 d before peptide injection
and covering the whole 3-wk immunization period).
Before the first immunization cycle, A2/Melan-A1 cells
(0.04% of CD81 T cells) presented a naive CD45RAhi
phenotype. In marked contrast, 1 mo after the end of the
first peptide injections and until the end of the second im-
munization cycle, half of the tetramer1 cells presented an
Ag-experienced CD45RAlo phenotype. This was accom-
panied by a small increase in the frequency of A2/Melan-
A1 cells (from 0.04 to 0.07% of CD81 T cells). During the
next year, the proportion of CD45RAloA2/Melan-A1 cells
gradually decreased (from 51 to 23% of A2/Melan-A1
cells), while the frequency of total A2/Melan-A1 cells re-
mained constant (z0.07%). Moreover, the vast majority of
A2/Melan-A1 cells continuously displayed a CD281
phenotype over time. Enumeration of tyrosinase-specific
CD81 lymphocytes using an available tetramer made with
the Tyrosinase368–376 peptide failed to reveal significant lev-
els of positive cells in the samples tested (September 1996,
June 1997, July 1997, and April 1998).
Discussion
Using tetrameric complexes (35), we have directly enu-
merated and phenotyped ex vivo melanoma-specific CD81
T cells present in peripheral blood. This study reveals that
circulating Melan-A–specific CD81 T cells are generally
present in high numbers both in melanoma patients and
healthy individuals. These cells present a naive phenotype
in healthy individuals, but may develop an Ag-experienced
phenotype in some melanoma patients. Furthermore, Ag-
specificity and phenotype of A2/Melan-A1 cells were in-
dependently confirmed by functional assays. As recorded
for one patient immunized with a Melan-A peptide,
marked and reversible shifts in the proportion of memory-
type circulating Melan-A–specific CTLs occurred in vivo.
In contrast, circulating influenza virus–specific CTLs in
most of the same individuals display a homogeneous mem-
ory phenotype.
Our findings confirm and extend previous reports on the
presence of circulating Melan-A–specific cells both in mel-
anoma patients and healthy individuals (6–9, 36). How-
ever, the necessity of stimulating CTLp with Ag in order to
detect Melan-A–specific cells had previously prevented a
precise assessment of their frequency and phenotype ex
vivo. We find here that circulating Melan-A–specific cells
are indeed present in a large proportion (60%) of healthy
individuals. Although this prevalence is in agreement with
that measured in the previous studies (20–75% of healthy
individuals), tetramer staining reveals for the first time that
the frequency of circulating Melan-A–specific cells is much
higher than had been anticipated (mean 5 z1/1,500 of
CD81 T cells) both in healthy individuals and melanoma
patients. These frequencies are underestimated consistently
by indirect assays, as demonstrated in this study by LDA
and IFN-g ELISPOT. Phenotypic analyses of A2/Melan-
A1 cells reveal that underestimation reflects the failure to
detect primarily, although not exclusively, CD45RAhi-spe-
cific cells. Thus, naive phenotype cells are less efficiently
stimulated during in vitro Ag-driven differentiation to ef-
fectors, as has been shown in experiments involving naive
phenotype cells challenged by Ag-independent TCR
cross-linking (37, 38).
Figure 5. Time course analysis of PBMCs from immunized melanoma
patient LAU 132 shows dramatic phenotype changes of A2/Melan-
A1CD81 T cells. CD81 lymphocyte populations from PBMCs of patient
LAU 132 collected at different time points were highly purified (.98%),
as illustrated in Fig. 1. The lymphocyte preparations were then stained
with A2/Melan-A tetramers together with anti-CD45RACYC and anti-
CD28FITC mAbs and analyzed immediately by flow cytometry. (A) The
patient received five immunization cycles, consisting of subcutaneous in-
jections of Melan-A26–35, Tyrosinase1–9, Tyrosinase368–376, gp100280–288,
and gp100457–466 tumor-associated Ags, and influenza matrix Flu-MA58–66
peptide. All cycles with the exception of the first included treatment with
GM-CSF. CD45RA phenotype of A2/Melan-A1 cells was analyzed be-
fore the first immunization cycle (left), during immunizations (middle),
and at the end of immunizations (right). (B) Percentage of A2/Melan-A1
cells in CD81 T cells was followed over time. Each arrow represents an
immunization cycle. (C) Proportions of CD281 (s) and CD45RAlo (d)
in gated A2/Melan-A1 cells were followed over time.
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The frequencies of naive single epitope-specific CTLp
have been estimated at #1/100,000 CD81 T cells. Thus, it
is striking that the mean frequency of circulating Melan-
A–specific cells from HLA-A21 healthy individuals is $60
times higher, in fact attaining the range of frequencies for
single epitope-specific memory CTLs. In this regard, since
Melan-A is a melanocyte lineage protein, it might be ar-
gued that enrichment of cells specific for the Melan-A26–35
peptide could result from frequent priming events after
common subclinical skin injuries in healthy individuals. Al-
ternatively, the Melan-A homologous peptide gC480–488,
derived from the unrelated glycoprotein C of the common
pathogen HSV-1 (39), could also be responsible for the
activation of Melan-A cross-reactive cells. However, the
observation that ex vivo A2/Melan-A1 cells from healthy
individuals are of the naive CD281CD45RAhi/RO2 phe-
notype does not support these hypotheses. It remains possi-
ble that CD28/CD45RA surface Ags do not reflect true
human Melan-A–specific naive T lymphocytes. For in-
stance, reversion of CD45RO1 T cells to CD45RA1 T
cells after prolonged in vitro culture periods has been ob-
served (40, 41). Although Flu-MA–specific CD81 T cells
from virtually all individuals studied displayed a memory
CD45RO1 phenotype, it remains to be ascertained
whether such a conversion may have taken place in Melan-
A–specific CD81 T cells in vivo. Nevertheless, our results
in no way rule out the possibility that Melan-A–specific
cells in healthy individuals as well as in the majority of mel-
anoma patients represent either truly naive T cells or cells
that have been partially activated (42, 43). This raises the
question as to how such relatively large repertoire of naive
T cells is maintained in the periphery. For instance, what
are the ligands and/or cytokines involved? Further pheno-
type and functional characterization of these cells are re-
quired to clarify these issues.
Does tetramer staining of Melan-A–specific cells reveal
differences between melanoma patients and healthy indi-
viduals? In terms of frequencies, Melan-A–specific cells
were generally found in high numbers in patients, but these
numbers were comparable with those measured in healthy
individuals. In contrast, and as previously reported (34), the
frequency of Melan-A–specific cells was even higher in pa-
tients undergoing vitiligo. Previous reports have shown
that development of vitiligo is more frequent in melanoma
patients (44), and that vitiligo may be associated with an
ongoing immune response directed against melanoma cells
(45, 46). This evidence suggests that melanocyte-specific
CTLs can play a role in melanocytic destruction. From a
clinical standpoint, the presence of high numbers of circu-
lating Melan-A–specific cells found in the majority of
HLA-A21 melanoma patients represents a unique opportu-
nity for vaccination protocols aimed at harnessing the po-
tential power of these CTLs to migrate to and destroy tu-
mors. In addition, polyclonal-specific T cell populations
could easily be obtained by tetramer-guided sorting and
used for adoptive transfer therapy (47).
The tetramer technology not only allows frequency
analyses, but opens the possibility to characterize pheno-
types corresponding to various differentiation stages of T
cells. We observed that the majority of influenza virus–spe-
cific CTLs were CD45RAlo, whereas the melanoma-spe-
cific CTLs were largely CD45RAhi. Finally, CD45RAlo
melanoma-specific CTLs were only observed in 3 out of
10 melanoma patients. The different expression of CD45
isoforms probably corresponds to different cellular activa-
tion status. Therefore, the fact that some patients, but no
healthy individuals, had CD45RAlo/RO1 Melan-A–spe-
cific cells may suggest that CTLs have been activated in
vivo as part of immune activation against melanoma cells.
When tracking a patient’s immune response over the
course of an immunotherapeutic treatment with Melan-
A26–35, we recorded a marked but reversible shift in the
proportion of memory-type Melan-A–specific cells. How-
ever, no changes in frequency or phenotype of Melan-
A–specific cells were observed after a similar immunization
schedule on a second melanoma patient (LAU 269). It is
not possible at this time to establish whether peptide vacci-
nation and/or GM-CSF administration were responsible
for the phenotype shifts observed in the former patient. A
larger group of vaccinated patients will be analyzed, as it is
possible that this vaccination procedure is not efficient. Im-
munization with potent adjuvants and Melan-A peptide
analogues with enhanced immunogenicity will be tested.
Direct detection of tumor-specific lymphocytes in the
periphery and in tumor-infiltrated LNs allowed us to ob-
tain a better appraisal of a tumor-specific response in vivo.
In tumor-infiltrated LNs, Melan-A–specific cells were en-
riched with frequencies ranging from 1/400 to 1/30 CD81
LN cells and displayed an Ag-experienced (CD45RAlo/
RO1) phenotype in most cases, as compared with noninfil-
trated adjacent LNs or LNs from patients with forms of
cancer other than melanoma (12). In contrast, circulating
Melan-A–specific cells were generally not enriched in mel-
anoma patients, as compared with healthy individuals and
with normal LNs. Moreover, they infrequently presented
Ag-experienced phenotypes. It is tempting to speculate
that the differences observed in both frequencies and sur-
face phenotype of Melan-A–specific CTLs are the conse-
quence of selective in vivo activation of these cells at infil-
trated LNs. It is also conceivable that primed cells are
selectively accumulated at infiltrated LNs. Together, our
findings emphasize the need to monitor both the tumor
sites and the periphery to thoroughly evaluate the impact of
natural or vaccine-induced tumor-specific CTL responses.
We would like to give special thanks to all of the patients for their enthusiastic collaboration. We gratefully
acknowledge Renate Milesi, Nicole Montandon, Danielle Minaïdis, and Christian Knabenhans for excellent
technical assistance. We also thank John Gordan for critical reading of this manuscript.
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